1Laird PW. Cancer epigenetics[ J ]. Hum Mol Genet,2005,14 ( 1 ) : R65- 76.
2Ji H, Wang Z, Perera SA, et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models[ J]. Cancer Res,2007,67 (10) :49334939.
3Duesbery N, Vande Woude G. BRAF and MEK mutations make a late entrance[ J]. Sci STKE ,2006,2006 ( 328 ) : 15.
4Kratz CP, Niemeyer CM, Zenker M. An unexpected new role of mutant Ras: perturbation of human embryonic development [ J ]. J Mol Med, 2007,85 ( 3 ) :227-235.
5Peltomaki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer : database and results of a collaborative study [ J ]. Gastroenterology, 1997,113 ( 11 ) : 1146-1158.
6Wang L, Cunningham JM, Winters JL, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair [ J ]. Cancer Res,2003,63 ( 17 ) :5209-5212.
7Fransen K, Klintenas M, Osterstrom A, et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas [ J ]. Careinogenesis, 2004,25 (4) :527-533.
8Oliveira C, Pinto M, Duval A, et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency [J]. Oncogene, 2003,22(57) :9192-9196.
9Nagasaka T, Sasamoto H, Notohara K, et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation [ J ]. J Clin Oncol,2004, 22(22) :4584-4594.
10Carr NJ, Mahajan H,Tan KL, et al. Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma[J]. J Clin Pathol,2009, [Epub ahead of print].
5Yoshimura C, Miyafusa T, Tsumoto K. Identification of small-molecule inhibitors of the human S100B-p53 interaction and evaluation of their activity in human melanoma cells[J]. Bioorg Med Chem, 2013,21 (5): 1109-1115.
6Byron SA, Loch DC, Wellens CL, et al. Sensitivity to the MEK inhibitor E6201 in melanoma cells is associat- ed with mutant BRAF and wildtype PTEN status[J]. Mol Cancer,2012,11 : 75.
7Wang J, Wang X, Chen Y, et al. Immunization with a HSP65-HER2 fusion peptide selectively eliminates HER2(+) B16 melanoma cells in a xenograft tumor mouse model[J]. Tumour Biol,2013,34(1): 193-201.
8Hansen W. Neuropilin 1 guides regulatory T cells into VEGF-producing melanoma [ J ]. Oncoimmunology, 2013, 2(2): e23039.
9Conrad WH, Swift RD, Biechele TL, et al. Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant mela- noma cells with Wnt/beta-catenin activation[J]. Cell Cycle,2012, 11(20) : 3724-3730.
